oa Southern African Journal of Anaesthesia and Analgesia - Dextropropoxyphene is dead? Long live... : guest editorial
On 20 April 2011, the Medicines Control Council (MCC) announced its decision to withdraw all dextropropoxyphene-(DPP-) containing products from the South African market within three months, because of stated safety risks and an insufficiently weighted risk-benefit profile. These risks refer to dose-related cardiac conduction abnormalities associated with QT prolongation, provoked by the main metabolite of DPP, norpropoxyphene.
Article metrics loading...